Company intelligence
BioCina
Your Agile CDMO Partner. From Clinical to Commercial.
About BioCina
BioCina is an agile, end-to-end CDMO partner with more than fifty years of pharmaceutical manufacturing heritage, supporting biologic drug substance and sterile drug product manufacturing for small molecules and biologics, from clinical through commercial. Our expertise spans microbial fermentation, pDNA, and mRNA drug substance with LNP encapsulation, as well as sterile fill-finish drug product for small molecules and biologics, covering cell line, process, analytical, and formulation development through cGMP clinical and commercial manufacturing. That agility carries through to how we work: we adapt quickly as programs evolve, scaling capacity and adjusting timelines to keep pace with your priorities. We're strategically located in Australia, offering faster pathways to first-in-human trials, backed by a stable regulatory environment and streamlined ethics approvals. Our facilities are led by subject matter experts with an average tenure of over 10 years, TGA licensed, and have passed inspections by the US FDA, EMA, Health Canada, and many more regulatory authorities. This combination, deep technical expertise and a customer-centric, agile approach, has built a proven track record supplying drug substance and sterile drug product to more than 140 countries, with your program's priorities front and centre from first-in-human through commercial supply. Australia also offers one of the world's most generous R&D tax incentives, up to 43.5% cash back, making BioCina an ideal partner for global biotechs looking to scale with speed and agility.
Verified activity
Signals from BioCina
2 published signals
Presence & Recognition
BioCina is attending the BIO-Europe event in Cologne, Germany from 9 to 11 November 2026.
Reported by BioCina
Presence & Recognition
BioCina team is exhibiting at the Cell & Gene Meeting on the Mesa in the USA, CPHI Milan in Italy, BioJapan in Japan, AusBiotech International Conference in Australia, and the 14th International mRNA Health Conference in the USA from 9–11 November.
Reported by BioCina